Medtronic plc
MDT
$99.94
-0.67%
Medtronic plc is one of the world's largest medical-device companies, developing and manufacturing therapeutic devices for chronic diseases across cardiac rhythm management, transcatheter heart valves, stents, surgical robotics, spinal fixation, neurovascular, advanced energy, and diabetes management, sold primarily to hospitals and physicians in the US, Western Europe, and Japan with roughly half of sales generated outside the US. It operates as a scaled incumbent platform in a consolidated oligopoly alongside Abbott, Boston Scientific, Stryker, and Intuitive Surgical, distinguished by the broadest therapeutic portfolio in medtech and a long-standing dividend franchise rather than by any single high-growth product line. The current investor debate centers on whether the Hugo surgical robot can finally mount a credible challenge to Intuitive Surgical's dominance following FDA approval, whether the cardiovascular and diabetes franchises can sustain the double-digit growth that drove the most recent quarter, and whether margin pressure and cautious forward guidance cap the re-rating. Recent coverage highlights a Q1 revenue and EPS beat with broad-based growth offset by margin concerns, alongside a narrative that MDT remains inexpensive relative to peers with a growing dividend — a setup that has attracted value-oriented buyers even as growth skeptics point to the PEG ratio and thin net margin.…
MDT
Medtronic plc
$99.94
Related headlines
Investment Opinion: Should I buy MDT Today?
Rating: Hold with a constructive lean toward accumulating on weakness. The core thesis is that Medtronic is a cash-generative medtech incumbent trading at a modest 22.2x trailing earnings and 13.5x EV/EBITDA while revenue reaccelerates to 13.73% YoY, but margin compression (operating margin 17.78% versus 19.66% in the January 2026 quarter) and the unproven Hugo robot against Intuitive Surgical cap the near-term re-rating. Analyst consensus is constructive but not enthusiastic — five Buy/Outperform ratings versus four Hold/Neutral and zero Sells across the ten most recent actions, with a $8.09 consensus EPS implying roughly 12.7x forward earnings at the $102.86 price.
Supporting evidence is genuinely balanced. On the positive side: revenue of $9.756 billion grew 13.73% YoY versus $8.578 billion a year ago; trailing free cash flow of $6.132 billion covers the $921 million quarterly dividend roughly 1.4x and supports a 3.41% yield; the stock trades at 2.94x sales and 2.16x book, both near the low end of multi-year ranges; and relative strength versus SPY is +32.95 points over six months and +11.42 over one month, confirming a real trend reversal off the $73.75 June low. On the negative side: net margin of 13.20% trails high-margin peers, the 75.8% payout ratio leaves limited cushion, the PEG ratio of 6.72 (however distorted by the questionable forward EPS input) flags the stock as not statistically cheap relative to growth, and the price sits at approximately 100% of its 52-week range after a 35.08% six-month run.
The biggest risks that would invalidate the thesis are (1) a further leg down in operating margin below the 17.78% print, which would compress the earnings base the 22.2x multiple sits on; (2) Hugo failing to gain meaningful traction against Intuitive Surgical's installed base, removing the high end of the $7.45-$8.29 EPS range; and (3) a breakdown below the $94-$95 support shelf that would signal the six-month advance is faltering. This Hold would upgrade to Buy if operating margin stabilizes above 19% while revenue growth holds in the low-to-mid teens, or if the stock pulls back toward the $86-$88 September consolidation zone without fundamental deterioration; it would downgrade to Sell if FY2027 guidance is cut or revenue growth decelerates below high-single digits. Valuation verdict: fairly valued to modestly undervalued relative to its own 18.6x-40.7x historical PE band and to high-growth medtech peers, but not a deep-value opportunity — the market is pricing improving fundamentals without yet awarding a premium multiple.
Sign up to view all
MDT 12-Month Price Forecast
Medtronic presents a genuinely balanced setup: the growth reacceleration to 13.73% and $6.132 billion of trailing free cash flow are real, and the 22.2x trailing PE is not stretched against a historical band that has run as high as 40.7x. But the margin trajectory is deteriorating — operating margin fell to 17.78% from 19.66% — and the stock has already priced in much of the improvement with a 35.08% six-month gain that leaves it at the top of its 52-week range. The Hugo optionality is real but unproven against Intuitive Surgical's installed base, and the thin six-analyst coverage means sentiment can swing sharply in either direction. I would upgrade to bullish on evidence of operating margin stabilizing above 19% alongside sustained low-to-mid-teens revenue growth, or on a pullback toward $86-$88 that restores risk/reward; I would downgrade to bearish if FY2027 guidance is cut or revenue growth decelerates below high-single digits.
Wall Street consensus
Coverage is moderate with six analysts contributing estimates, and the institutional ratings flow is constructive: of the ten most recent ratings actions, five are Buy/Outperform/Overweight (BTIG, TD Cowen, UBS, Wells Fargo, RBC, B of A) and four are Hold/Neutral (Baird, Stifel, Truist), with no Sell ratings — a consensus that leans bullish but with meaningful caution. The consensus EPS estimate of $8.09 (range $7.45 to $8.29) against a $102.86 share price implies a forward multiple of roughly 12.7x, which is inexpensive for a company growing revenue 13.7% and would represent a compelling valuation if achieved. Consensus revenue of $45.99 billion (range $43.21 billion to $46.87 billion) implies continued mid-single-to-high-single-digit growth on the current run-rate. Explicit price targets are not provided in the data, so a precise implied upside cannot be calculated; however, the analyst EPS estimates and the uniformly non-negative ratings skew suggest the Street sees the stock as fairly to attractively valued at current levels. The target range itself is unavailable, but the EPS dispersion — a low of $7.45 versus a high of $8.29, a spread of about 11% around the $8.09 mean — signals moderate rather than extreme uncertainty in earnings expectations. The high end of the range would assume successful Hugo robot commercialization, sustained cardiovascular and diabetes momentum, and margin stabilization; the low end would reflect continued margin compression, competitive pressure from Intuitive Surgical and Boston Scientific, and cautious guidance playing out. Notably, the ratings actions are overwhelmingly reiterations rather than upgrades or downgrades, indicating analysts are in a wait-and-see posture ahead of further evidence on the growth and margin trajectory; the absence of any downgrades despite the margin-pressure narrative is a mildly positive signal. With only six analysts covering a $107 billion market-cap company, coverage is thinner than one would expect for a mega-cap medtech, which may reflect the stock's long period of underperformance and could contribute to the sharp relative-strength swings observed — but the recent cluster of Buy reiterations from BTIG, TD Cowen, UBS, and B of A suggests institutional conviction is rebuilding as the fundamentals improve.
Bulls vs Bears: MDT Investment Factors
The bull case currently has stronger evidence: revenue is accelerating at 13.73% YoY, free cash flow of $6.132 billion comfortably funds a 3.41% dividend, the stock trades at a historically modest 22.2x trailing PE, and analyst sentiment is constructive with five Buy ratings and zero Sells. The bear case rests on genuine but secondary concerns — operating margin of 17.78% is below the 19.66% January quarter, net margin of 13.20% trails high-margin peers, and the stock is technically extended at 100% of its 52-week range after a 35% six-month rally. The single most important tension is whether the cardiovascular and diabetes franchises can sustain double-digit growth long enough for Hugo to become a credible second growth engine before margin pressure and cautious guidance stall the re-rating. If growth holds and margins stabilize, the current 22.2x PE has room to expand toward its historical midpoint; if growth decelerates or Hugo disappoints, the stock's premium-free valuation offers only modest downside protection given the thin 13.20% net margin.
Bullish
- Revenue reaccelerating to 13.7% YoY: Q1 FY2027 revenue of $9.756 billion grew 13.73% year-over-year versus $8.578 billion in the year-ago quarter, a clear acceleration from the $9.018 billion and $9.807 billion prints in the two preceding periods. This supports the thesis that Medtronic is shifting from a low-growth stalwart toward double-digit top-line expansion, which would justify a higher multiple if sustained.
- Cheap valuation versus growth and history: At $102.86 the stock trades at 22.2x trailing earnings, 2.94x sales, and 13.5x EV/EBITDA — moderate for a large-cap medtech growing revenue 13.7%. The trailing PE sits in the lower-middle of its historical 18.6x-40.7x band, closer to the trough than the peak, leaving room for re-rating if growth and margins hold.
- Strong free cash flow covers dividend: Trailing-twelve-month free cash flow of $6.132 billion comfortably covers the $921 million quarterly dividend and $267 million of buybacks, with quarterly FCF of $1.29 billion against $1.793 billion in operating cash flow. The 3.41% dividend yield, well above the sector norm, provides a valuation floor that pure-growth peers lack.
- Analyst consensus leans constructive: Of the ten most recent ratings actions, five are Buy/Outperform/Overweight (BTIG, TD Cowen, UBS, Wells Fargo, RBC, B of A) and four are Hold/Neutral, with no Sell ratings. The absence of any downgrades despite the margin-pressure narrative is a mildly positive signal, and the $8.09 consensus EPS implies roughly 12.7x forward earnings.
Bearish
- Margin compression is real and persistent: Operating margin of 17.78% in the latest quarter sits below the 19.66% recorded in the January 2026 quarter, and gross margin of 64.99% is well below the 75.87% reported in the April 2026 quarter. Heavy SG&A of $3.198 billion and R&D of $771 million constrain operating leverage, and cautious FY2027 guidance flagged in recent coverage caps the re-rating case.
- PEG ratio of 6.72 signals expense: A PEG ratio of 6.72 on a 22.2x trailing PE implies the stock is expensive relative to its growth rate, even accounting for the questionable forward EPS input. The extraordinarily wide gap between trailing PE of 22.2x and forward PE of 6.72x likely reflects a data artifact, so investors cannot rely on the forward multiple as a genuine valuation anchor.
- Thin net margin versus peers: Net margin of 13.20% is respectable for a scaled device manufacturer but far below the 20%+ net margins of higher-margin peers like Intuitive Surgical. The gap between 64.99% gross margin and 13.20% net margin reflects the heavy spending burden that limits earnings upside even as revenue grows.
- Hugo faces formidable incumbent barrier: Medtronic's FDA approval for the Hugo surgical robot is a major milestone, but Intuitive Surgical's massive head start and installed base present a formidable barrier to true market leadership, per recent coverage. The high end of the analyst EPS range ($8.29) assumes successful Hugo commercialization, so any disappointment removes a key pillar of the bull case.
MDT Technical Analysis
MDT is in a sustained, powerful uptrend that has accelerated decisively over the past six months: the stock is up 35.08% over six months and 6.99% over one year, closing at $102.86 against a 52-week range whose low sits near the $73.75 area touched in early June 2026. That places the current price at approximately 100% of its 52-week range — effectively at the highs — a positioning that signals strong momentum but also raises the risk of overextension and profit-taking after a 30% max drawdown earlier in the cycle. The move from roughly $73.81 on May 29 to $102.86 on November 13 represents a recovery of nearly 39% off the lows, confirming a genuine trend reversal rather than a dead-cat bounce. Short-term momentum is clearly accelerating and diverging positively from the longer-term record: the stock gained 9.16% in the last month and 12.70% in the last three months, versus a 6.99% one-year gain, meaning most of the annual return was generated in the recent leg higher. Relative strength versus SPY is striking — +11.42 percentage points over one month, +15.53 over three months, and +32.95 over six months — even as the one-year relative strength remains negative at -5.28, a divergence that suggests MDT is in the early-to-middle innings of a catch-up trade after a prolonged period of underperformance. The most recent sessions show the stock consolidating just below the $104.96 intraday-area high set on November 4, with closes of $101.59, $101.61, $100.99, and $102.86 — a tight, constructive pause rather than a breakdown. Key resistance sits at the $104.96 recent high; a clean breakout above that level on volume would confirm the uptrend's continuation and open blue-sky territory, while support is anchored at the $94-$95 shelf (multiple October closes) and, more fundamentally, at the $73.75 52-week low. A breakdown below $94 would signal the six-month advance is faltering and likely target the $86-$88 September consolidation zone. Beta is not provided in the data, but the 30% max drawdown and the stock's 39% rebound within roughly five months imply above-market realized volatility; position sizing should account for the possibility of sharp 10-15% retracements even within an intact uptrend.
Beta
—
—
Max Drawdown
-30.0%
Largest decline past year
52-Week Range
—
Price range past year
Annual Return
+0.6%
Cumulative gain past year
| Period | MDT Return | S&P 500 |
|---|---|---|
| 1m | +7.4% | -9.7% |
| 3m | +7.1% | -9.9% |
| 6m | +27.2% | -7.5% |
| 1y | +0.6% | +4.7% |
| ytd | +4.0% | +1.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MDT Fundamental Analysis
Revenue is growing at a healthy and improving clip: the most recent quarter (period ending 2026-07-31) delivered $9.756 billion in revenue with 13.73% year-over-year growth, a marked acceleration from the $8.578 billion reported in the year-ago quarter and above the $9.807 billion and $9.018 billion prints in the two preceding periods. The segment mix shows the Cardiac and Vascular Group as the largest contributor at $3.927 billion, followed by Neuroscience at $2.678 billion, Medical Surgical at $2.279 billion, and Diabetes at $843 million — with the cardiovascular and diabetes franchises identified in recent coverage as the primary growth engines offsetting softer areas. This trajectory supports the bull case that Medtronic is no longer a low-growth medtech stalwart but is reaccelerating toward double-digit top-line expansion, a shift that would justify a higher multiple if sustained. Profitability is solid but not exceptional: net income was $1.47 billion in the latest quarter on a 64.99% gross margin and 17.78% operating margin, with a net margin of 13.20% — respectable for a scaled device manufacturer but below the 20%+ net margins of higher-margin peers like Intuitive Surgical. Margin trends are mixed: gross margin of 64.99% in the latest quarter compares favorably to 60.32% in the year-ago Q2 but is below the 75.87% reported in the April 2026 quarter, and the operating margin of 17.78% sits below the 19.66% recorded in the January 2026 quarter, consistent with the margin pressure flagged in recent news. The company remains firmly profitable with positive EPS of $1.15 in the latest quarter and $0.0449 on a trailing basis per the key metrics, but the thin net margin relative to gross margin reflects heavy SG&A ($3.198 billion) and R&D ($771 million) spending that constrains operating leverage. The balance sheet is sound: debt-to-equity of 0.565 is moderate for a capital-intensive medtech, the current ratio of 2.13 indicates ample short-term liquidity, and ROE of 9.70% is modest but positive. Free cash flow is the standout — $6.132 billion on a trailing-twelve-month basis, with quarterly FCF of $1.29 billion in the latest period against $1.793 billion in operating cash flow and $503 million of capex — comfortably covering the $921 million quarterly dividend and $267 million of buybacks. The dividend payout ratio of 75.8% is elevated and leaves limited room for error, but with FCF covering dividends roughly 1.4x on a quarterly basis, the 3.41% yield appears secure; the company is self-funding and does not depend on external financing for growth.
Quarterly Revenue
$9.8B
2026-07
Revenue YoY Growth
+13.7%
YoY Comparison
Gross Margin
65.0%
Latest Quarter
Free Cash Flow
$6.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MDT Overvalued?
Because Medtronic is solidly profitable (net income of $1.47 billion in the latest quarter and positive trailing EPS), the PE ratio is the appropriate primary metric. The stock trades at a trailing PE of 22.22x versus a forward PE of just 6.72x — an extraordinarily wide gap that, if the forward estimate is reliable, implies the market expects a dramatic earnings step-up; however, the forward figure appears inconsistent with the $8.09 average analyst EPS estimate against a $102.86 price (which would imply roughly 12.7x forward earnings), so the 6.72x forward PE should be treated with caution as it likely reflects a data artifact or a non-standard EPS basis. The more defensible read is a trailing PE of 22.2x against a PEG ratio of 6.72, which on its face suggests the stock is expensive relative to its growth rate — though the PEG calculation is sensitive to the same questionable forward EPS input. On other measures the stock looks reasonable: price-to-sales of 2.94x, price-to-book of 2.16x, and EV/EBITDA of 13.54x are all moderate for a large-cap medtech with mid-teens revenue growth. Peer comparison is constrained by the absence of explicit industry-average multiples in the provided valuation data, but the qualitative picture is clear: MDT's 22.2x trailing PE and 13.5x EV/EBITDA sit at a discount to high-growth medtech peers such as Intuitive Surgical (typically 50x+ earnings) and roughly in line with diversified device peers like Abbott and Boston Scientific, while its 2.94x PS ratio is modest for a company growing revenue 13.7%. The 3.41% dividend yield is well above the sector norm and provides a valuation floor that pure-growth peers lack. Historically, MDT's PE has ranged from roughly 18.6x (July 2026) to 40.7x (April 2024), with the current 22.2x sitting in the lower-middle portion of that band — closer to the trough than the peak. Its PS ratio of 2.94x is near the low end of a historical range that has spanned roughly 10.6x to 17.9x on the reported quarterly series (noting a scale inconsistency in the historical data), and its PB of 2.16x is near the bottom of a 1.79x-3.10x multi-year band. The takeaway is that despite the sharp price rally, MDT is not trading at historically stretched multiples; the market is pricing in improving fundamentals without yet awarding a premium multiple, which leaves room for further re-rating if growth and margins hold.
PE
22.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 19x~37x
vs. Industry Avg
26.4x
Industry PE ~26.4x*
EV/EBITDA
13.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on margin compression and dividend coverage. Operating margin of 17.78% in the latest quarter is below the 19.66% January 2026 level, and gross margin of 64.99% is well below the 75.87% April quarter, while SG&A of $3.198 billion and R&D of $771 million consume most of the gross profit. The 75.8% dividend payout ratio is elevated and leaves limited room for error, though quarterly FCF of $1.29 billion covers the $921 million dividend roughly 1.4x. Revenue concentration in Cardiac and Vascular ($3.927 billion of $9.756 billion) means any slowdown in that franchise would disproportionately hit the growth story, and debt-to-equity of 0.565 with $186 million of quarterly interest expense adds a fixed charge against volatile earnings.
Market and competitive risks include valuation compression and a formidable robotic rival. At 22.2x trailing earnings and a PEG of 6.72, the stock is not cheap relative to its growth rate, and the wide gap between trailing PE (22.2x) and forward PE (6.72x) suggests the market may be relying on an unreliable earnings step-up. Intuitive Surgical's installed base and head start present a formidable barrier to Hugo, and Boston Scientific's cyberattack-driven Q4 guidance cut (October 28) illustrates how quickly operational shocks can hit medtech peers. The stock's 30% max drawdown and 39% rebound within five months imply above-market realized volatility, and with only six analysts covering a $107 billion market cap, thin coverage can amplify sharp relative-strength swings.
Worst-case scenario: margin compression persists, FY2027 guidance is cut, and Hugo fails to gain traction against Intuitive, triggering analyst downgrades and a de-rating toward the low end of the historical PE band. A retest of the $73.75 52-week low from the current $102.86 would represent a loss of roughly 28%, and a move to the $86-$88 September consolidation zone would be about a 14-16% decline. The 30% historical max drawdown provides a realistic ceiling on downside, meaning an investor could lose approximately 28-30% in a severe adverse scenario.
FAQ
The most severe risk is margin compression: operating margin fell to 17.78% from 19.66% in the January 2026 quarter, and gross margin of 64.99% is well below the 75.87% April print, with SG&A of $3.198 billion and R&D of $771 million consuming most of gross profit. Second is competitive execution on Hugo, where Intuitive Surgical's installed base and head start present a formidable barrier and disappointment would remove the $8.29 high end of the EPS range. Third is valuation and momentum risk — a PEG of 6.72 and a stock at 100% of its 52-week range after a 35% rally leave little room for error, with a 30% historical max drawdown framing downside. Fourth is financial flexibility: a 75.8% dividend payout ratio and debt-to-equity of 0.565 with $186 million of quarterly interest expense limit maneuverability if earnings disappoint.
The 12-month outlook splits into a 50% base case of $100-$115, a 25% bull case of $118-$128, and a 25% bear case of $74-$88. The base case assumes consensus revenue of $45.99 billion and EPS near $8.09 with the multiple holding in the low-20s trailing, letting the 3.41% dividend contribute roughly a third of total return. The bull case requires credible Hugo traction, cardiovascular and diabetes growth above 10%, and operating margin recovering toward 19.66%, driving EPS to the $8.29 high end and a re-rating to 14-15x. The bear case assumes margin compression persists, FY2027 guidance is cut, and Hugo disappoints, de-rating the stock toward the $73.75 low. The base case is most likely, hinging on margin stabilization rather than further deterioration.
MDT looks fairly valued to modestly undervalued on most measures. The 22.2x trailing PE sits in the lower-middle of its 18.6x-40.7x historical band, price-to-sales of 2.94x and price-to-book of 2.16x are near the low end of multi-year ranges, and EV/EBITDA of 13.5x is moderate for a large-cap medtech growing revenue 13.7%. The caveats are a PEG ratio of 6.72 and a forward PE of 6.72x that is inconsistent with the $8.09 consensus EPS against a $102.86 price (implying roughly 12.7x), so the forward multiple should be treated as unreliable. The market appears to be pricing in improving fundamentals without yet awarding a premium multiple, which leaves room for re-rating if margins stabilize but offers limited cushion if growth stalls.
From a risk/reward standpoint MDT is reasonably attractive but not compelling at $102.86. The upside case rests on a 22.2x trailing PE that sits in the lower-middle of a historical 18.6x-40.7x band, 13.73% revenue growth, $6.132 billion of trailing free cash flow, and a 3.41% dividend yield, with five Buy ratings and zero Sells across the ten most recent analyst actions. The downside is that the stock has already rallied 35.08% in six months to roughly 100% of its 52-week range, operating margin has slipped to 17.78% from 19.66%, and a retest of the $73.75 low would mean about a 28% loss. It is a good buy for patient, income-oriented investors accumulating on pullbacks toward the $86-$88 zone, and a less attractive entry for anyone buying the current extension without a margin-stabilization catalyst.
MDT is better suited to a long-term hold than a short-term trade. It is a mature, scaled medtech platform with $6.132 billion of trailing free cash flow, a 3.41% dividend yield, a 75.8% payout ratio, and a 54-year listing history since 1972 — characteristics that reward patience rather than tactical positioning. The 30% max drawdown and 39% rebound within roughly five months imply above-market realized volatility, so short-term traders face sharp 10-15% retracements even within an intact uptrend. Earnings visibility is moderate given cautious FY2027 guidance and only six analysts covering a $107 billion market cap. A minimum holding period of 12-24 months is appropriate to capture the dividend, allow Hugo to prove out, and let margin trends normalize, with entry on weakness toward $86-$88 preferred over chasing the current 52-week high.

